Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans

Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.

Divergent quality-of-life results from two glioblastoma studies of Avastin (bevacizumab) could complicate Genentech Inc.’s regulatory prospects for expanding the VEGF inhibitor’s use to the first-line setting.

The mixed data from two Phase III studies – one sponsored by parent company Roche, the other by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America